BioSpace News Archive

We interviewed Patti Rossman, president of Globiox and co-founder of the Life Science Women’s Conference. Patti shared her insights from a diverse career with large organizations and in consulting.

We challenge you to stop doing these things next week and see how your work productivity skyrockets. So practice avoiding these productivity killers at work.

The reclassification of prescription drugs and the increasing trend for self-care are two factors which drive growth of the global over-the-counter drugs and dietary supplements market, according to a report by BCC Research, “Over-the-Counter Drugs and Dietary Supplements: Opportunities for Consumer Goods Distributors.”

If successful, the CEO told BioSpace in an exclusive interview that Acelarin will break the glass ceiling as the first FDA-approved treatment for biliary tract cancer.

Bittium exhibits its innovative products and solutions for cardiology and neurology at Medica 2019, the leading international trade fair for the medical sector, on November 18-21 in Dusseldorf, Germany.

Levo Therapeutics, Inc. announced that the U.S. Food and Drug Administration has granted Fast Track designation for LV-101 for the treatment of Prader-Willi syndrome Levo is currently enrolling participants in its Phase 3 clinical study of intranasal carbetocin for the treatment of PWS.

Shaun Grannis, M.D., M.S., an internationally recognized expert in informatics, data analytics, and biosurveillance, has been named the Regenstrief Institute’s first vice president of data and analytics.

Amarantus Bioscience Holdings, Inc. released a letter to its shareholders following the announcement of the binding term sheet to license the Company’s therapeutics subsidiaries’ technologies to Emerald Organic Products, an emerging CBD-focused health sciences company, and other recent events

Frontage Clinical Services Inc. announced the implementation of ClinSpark®, a web-based eSource platform, that supports activities from subject recruitment through database lock.

WuXi Biologics congratulates its partner Tychan on successful completion of the Phase 1A/1B safety and efficacy trials in Singapore for TY014, a first-in-class monoclonal antibody candidate treatment for Yellow Fever